Pharmaceutical Products M&A Transactions

Prestige Consumer Healthcare acquires a $1.045B OTC portfolio including Breathe Right from Foundation Consumer Healthcare, sharpening Foundation's focus on Women's Health.

Shionogi & Co., Ltd. invests $2.5 billion in RADICAVA, building a rare disease platform and enhancing its ALS treatment offerings.

Sycamore Partners aims to double Walgreens' profitability to $4B following its $10B acquisition, implementing operational and cost-saving strategies.

Global pharma major Lupin Limited completes acquisition of VISUfarma B.V., significantly expanding its ophthalmology portfolio and European market reach.

Cyclerion Therapeutics

Korsana Biosciences and Cyclerion Therapeutics merge, backed by $380M financing. Focus on advancing Alzheimer's drug KRSA-028 and neurodegenerative pipeline.

Axsome Therapeutics

Axsome Therapeutics secures global rights to balipodect, a novel PDE10A inhibitor, aiming to enhance its neuroscience portfolio for neuropsychiatric conditions.

CapVest Partners completes €10 billion acquisition of STADA Arzneimittel AG, a leading global healthcare company, from Bain Capital and Cinven.

Two Great Helms Stock

Iconic Chinese herbal toothpaste maker Two Great Helms faces a controlling shareholder change amid declining profits. Potential acquirers identified.

Biogen secures Apellis Pharmaceuticals in a $5.6 billion deal, enhancing its immunology and rare disease offerings with two approved therapies and expanding nephrology reach.

Eli Lilly and Company announces $6.3 billion acquisition of Centessa Pharmaceuticals, expanding its neuroscience focus on sleep-wake disorder treatments.

Biogen Inc. secures Apellis Pharmaceuticals for $5.6 billion, enhancing its rare disease and immunology portfolio with key therapies for kidney conditions and macular degeneration.

CVC Capital Partners submits a $12.6B non-binding offer to acquire full control of Italian pharmaceutical firm Recordati, signaling a major European healthcare buyout.

Gilead Sciences acquires Ouro Medicines for $1.675B upfront, plus milestones, to advance its autoimmune T cell therapy pipeline.

CVC Capital Partners submits a €10.9 billion non-binding offer to acquire Recordati S.p.A., aiming to take the Italian pharmaceutical company private.

Curia

Carlyle and GTCR are reportedly exploring divestiture of Curia's Spanish pharmaceutical operations. Rothschild hired to manage potential sale of key CDMO assets.

Ferrer divests consumer health division Ferrer for You, featuring the popular Gelocatil brand, to a foreign multinational, refocusing on core pharma R&D.

Embecta Corp. buys Owen Mumford Holdings for up to £150M, enhancing its drug delivery platform for obesity, autoimmune diseases, and more.

Novartis secures a next-generation PI3Kα inhibitor for $2B, enhancing its targeted breast cancer therapy pipeline and precision medicine focus.

Paratek Pharmaceuticals

Paratek Pharmaceuticals integrates Radius Health, establishing a $1 billion specialty commercial platform with NUZYRA, XHANCE, and TYMLOS, backed by B-FLEXION Life Sciences.

CureBay expands rural healthcare access by acquiring Saveo's pharma distribution network, including 10,000+ pharmacies and key logistics hubs.

BriaPro Therapeutics Corp. secures exclusive rights to Soluble CD80 (sCD80) from BriaCell Therapeutics Corp. in a strategic oncology pipeline consolidation.

Zevra Therapeutics divests AZSTARYS® and KP1077 to Commave Therapeutics for $50M, resolving litigation and reinforcing its rare disease strategy.